Cohen I J, Kaplinsky C, Katz K, Mor C, Goshen Y, Yaniv Y, Avidor I, Yosipovitch Z, Zaizov R
Sambur Center for Pediatric Hematology Oncology, Beilinson Medical Center, Petah Tikva, Israel.
Isr J Med Sci. 1993 Jan;29(1):27-9.
Analysis of treatment results in osteogenic sarcoma patients with classical limb primary tumors and without metastasis at diagnosis or major protocol violations showed improved prognosis with a minimum follow-up of over 5.5 years when divided by years of treatment for all event-free survivors. Twelve patients treated in 1980-86 had a 5-year disease-free survival of 67% and 9 treated in 1973-79 had a 5-year disease-free survival of 33% (P = 0.0368). The improvement appeared to reflect the increase in the intensity of the chemotherapy utilized. Definitive surgery, amputation or limb salvage did not affect the outcome. With these surgical approaches the disease-free survival was 67% and 60% respectively.
对诊断时无转移或无重大方案违规的经典肢体原发性骨肉瘤患者的治疗结果分析显示,在对所有无事件幸存者按治疗年份进行划分时,最短随访超过5.5年,预后有所改善。1980 - 1986年接受治疗的12例患者5年无病生存率为67%,1973 - 1979年接受治疗的9例患者5年无病生存率为33%(P = 0.0368)。这种改善似乎反映了所用化疗强度的增加。根治性手术、截肢或保肢手术均不影响治疗结果。采用这些手术方法时,无病生存率分别为67%和60%。